EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis

Ahmed Elmosalamy iD, Idil Tarikogullari, Liliana Patarroyo-Rodriguez, Gwen Wilson, Jennifer L Vande Voort, Simon Kung, Mark A Frye, Balwinder Singh iD

Therapeutic Advances in Psychopharmacology · 2025-11 · 15

DOI: 10.1177/20451253251394127 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 13.11.2025. Verfasst von Ahmed Elmosalamy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Depression affects approximately 5.7% of adults worldwide, and around one-third of these individuals develop treatment-resistant depression (TRD). Intravenous (IV) ketamine and esketamine (administered IV or intranasally (IN)) are novel treatment options for TRD; however, only IN esketamine currently holds FDA approval.

Objectives

Compare the acute effectiveness of IV ketamine with esketamine (IV or IN) in adults with TRD.

Design

Mantel–Haenszel random-effects meta-analysis of head-to-head studies. Response and remission at study end point were co-primary outcomes, expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Subgroup and sensitivity analyses explored the impact of diagnosis, study type, and publication format; heterogeneity was quantified with I 2 . Data sources and methods: MEDLINE, Embase, Cochrane, APA Psycinfo, and Scopus were searched from inception through 19 March 2025. Eligible studies enrolled adults with unipolar or bipolar depression directly comparing IV ketamine with esketamine and reporting response or remission.

Results

Screening 1089 records identified eight studies ( n = 978). Seven observational studies ( n = 915) comparing IV ketamine with IN esketamine were included in the meta-analysis, while one randomized controlled trial (RCT) comparing IV formulations was summarized qualitatively. Pooled response from six studies gave OR = 1.26 (95% CI, 0.92–1.71; p = 0.15) and remission from seven studies gave OR = 1.31 (95% CI, 0.93–1.86; p = 0.12), both nonsignificantly favoring IV ketamine with negligible heterogeneity ( I 2 = 0%). Sensitivity analyses excluding bipolar depression or abstract-only reports yielded similar effect estimates, reinforcing the robustness of the findings. Evidence across three studies for faster onset with IV ketamine ranged from significant in one study to modest trends in two.

Conclusion

Based on the currently available comparative evidence, which is almost entirely observational, IV ketamine and IN esketamine show comparable acute response and remission rates, though IV ketamine may act faster. Large head-to-head RCTs are needed to confirm these findings.

Trial registration

The study protocol was prospectively registered on the Open Science Framework (OSF) at https://osf.io/5jzev .

Schlagwörter

Stichwörter der Autor:innen

depressionesketamineintranasalintravenousketaminemeta-analysisrapid-acting antidepressantssystematic review

Autor:innen und Institutionen

  • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
  • Mayo Clinic Libraries, Rochester, MN, USA.
  • Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

ORCID-Profile: Ahmed Elmosalamy, Balwinder Singh

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Elmosalamy, A., Tarikogullari, I., Patarroyo-Rodriguez, L., Wilson, G., Vande Voort, J. L., Kung, S., Frye, M. A., & Singh, B. (2025). Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology, 15. https://doi.org/10.1177/20451253251394127

Vancouver

Elmosalamy A, Tarikogullari I, Patarroyo-Rodriguez L, Wilson G, Vande Voort JL, Kung S, et al. Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology. 2025;15. doi:10.1177/20451253251394127

BibTeX
@article{Elmosalamy2025,
  author = {Elmosalamy, Ahmed and Tarikogullari, Idil and Patarroyo-Rodriguez, Liliana and Wilson, Gwen and Vande Voort, Jennifer L and Kung, Simon and Frye, Mark A and Singh, Balwinder},
  title = {Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis},
  journal = {Therapeutic Advances in Psychopharmacology},
  year = {2025},
  volume = {15},
  doi = {10.1177/20451253251394127}
}
Kostenlos starten →